Results of the analysis demonstrated that the only predictor for EDA was the expression of TNF in MS patients at baseline (Table 5), implicating that increased baseline expression of TNF was associated with higher probability of developing EDA during ocrelizumab treatment. This evidence concerns the gene TNF and myeloid sarcoma.